Speciality: Hematology

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy 5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL 1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01 2:52
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01
David Sallman • 11 Dec 2022
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL 3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda • 11 Dec 2022
Phase I study of CC-98633 in R/R multiple myeloma 2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa • 11 Dec 2022
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma 1:00
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma
Mazyar Shadman • 9 Dec 2022
CART19-BE-01: ARI-0001 in CD19+ malignancies 8:17
CART19-BE-01: ARI-0001 in CD19+ malignancies
Valentín Ortiz-Maldonado • 11 Oct 2020
Cellular therapies: from academia to industry 1:58
Cellular therapies: from academia to industry
Jürgen Kuball • 1 Sep 2020
Meta-analysis: anti-BCMA CAR-T in R/R myeloma 5:03
Meta-analysis: anti-BCMA CAR-T in R/R myeloma
Nico Gagelmann • 1 Sep 2020
Real-world efficacy & safety data: CAR-T in DLBCL 3:05
Real-world efficacy & safety data: CAR-T in DLBCL
Matthew Frigault • 1 Sep 2020
Challenges associated with CAR T-cell production 1:45
Challenges associated with CAR T-cell production
Valentín Ortiz-Maldonado • 1 Sep 2020
Gene editing: legal and ethical considerations 5:43
Gene editing: legal and ethical considerations
Aurélie Mahalatchimy • 1 Sep 2020
Gamma delta T-cell therapy 1:35
Gamma delta T-cell therapy
Jürgen Kuball • 1 Sep 2020
Future of anti-BCMA CAR T-cell therapy in myeloma 3:39
Future of anti-BCMA CAR T-cell therapy in myeloma
Noopur Raje • 1 Sep 2020
The potential of gene-edited effector cell therapy 2:40
The potential of gene-edited effector cell therapy
Maksim Mamonkin • 1 Sep 2020
The content of VJRegenMed is intended for healthcare professionals